IMproveMF Update: Phase 1/1B Trial of Imetelstat + Ruxolitinib in Patients With Intermediate-1, Intermediate-2, or High-Risk Myelofibrosis

Geron Corporation published this content on May 22, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on June 03, 2025 at 00:02 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at support@pubt.io